Residual Function Mutations in Cystic Fibrosis: An Important Target for Treatment - Certificate of Completion
Cystic fibrosis remains one of the most common life-shortening rare diseases, affecting about 85,000 individuals worldwide. Novel therapeutic approaches, including CFTR modulators, can offer clinical benefit to people with CF, producing improvements across numerous relevant endpoints.
Fellows of The Royal Australasian College of Physicians (RACP) can claim CPD credits in MyCPD for participation in this course. www.racp.edu.au/mycpd (log in to MyCPD). This interactive online learning activity is valued at 1Hour(s) of continuing education.
Margarida D Amaral
Professor, Faculty of Sciences
University of Lisbon, Portugal
Centre Director, Adult CF Service, Westmead Hospital, Sydney
Clinical Professor, University of Sydney
Chief Investigator, Ludwig Engel Centre for Respiratory Research,
Westmead Institute for Medical Research, Sydney
Upon completion of this program, participants will be able to:
- Discuss and differentiate the non-invasive prenatal testing (NIPT) options.
- Describe new developments in NIPT, which will allow appropriate ordering.
- Counsel patients about the benefits, limitations, test-result interpretation, and outcomes of different NIPT methodologies for trisomies 21, 18, and 13, microdeletions, sex chromosome aneuploidies, and triploidy in the primary care setting.